ArticleCureus2025
Topical Management Strategies for Acneiform Eruptions Induced by Cancer Drugs.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acneiform drug eruptions-update on pathophysiology and culprit drugs.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcneiform eruptions are common dermatological side effects of cancer therapies, particularly those involving tyrosine kinase inhibitors (TKIs) and epidermal growth factor receptor (EGFR) inhibitors, and can significantly impact patients' quality of life.
objectiveThe primary objective of this study was to evaluate the effectiveness of various topical therapies for managing cancer drug-induced acneiform eruptions and to assess patient-reported outcomes. Secondary objectives include comparing tolerability profiles and examining associations between malignancy types, treatment regimens, and eruption patterns. MATERIALS AND
methodsThis prospective observational study was conducted from January to December 2023 at the Departments of Dermatology, Abbas Institute of Medical Sciences (AIMS), Muzaffarabad, and Pakistan Institute of Medical Sciences (PIMS), Islamabad, Pakistan. A total of 116 patients aged 18 years or older who developed acneiform eruptions following cancer therapy were enrolled. Participants received topical treatments, including corticosteroids, benzoyl peroxide, metronidazole, retinoids, and antibiotics (clindamycin or erythromycin). Clinical assessments included lesion count, severity grading, and patient-reported outcomes (pain, itching, quality of life), recorded at baseline and at 2-, 4-, and 8-week follow-ups. Data analysis was performed using IBM SPSS Statistics for Windows, Version 26.0 (Released 2018; IBM Corp., Armonk, NY, US). Treatment efficacy comparisons were made using chi-square tests for categorical variables, t-tests for continuous variables, and multiple linear regression to identify independent predictors of lesion reduction.
resultsAntibiotics were the most commonly used treatment (30 patients, 25.86%), followed by benzoyl peroxide (27 patients, 23.28%) and corticosteroids (25 patients, 21.55%). By week 8, 99 patients (85.35%) presented with only mild lesions. Topical antibiotics (clindamycin/erythromycin) demonstrated the highest effectiveness, with a mean lesion count reduction of 7.2 ± 1.8 and severity reduction score of 3.6 ± 1.2, achieving an overall efficacy of 54%. Multiple linear regression analysis identified a later onset of acneiform eruptions (>5 weeks after therapy initiation) as a significant predictor of greater lesion reduction (β = -0.30, p = 0.047). Metronidazole was associated with the lowest incidence of adverse effects (2 patients, 13.33%). Both topical antibiotics and benzoyl peroxide significantly reduced lesion count and severity.
conclusionThese findings suggest that topical antibiotics, benzoyl peroxide, and corticosteroids are effective in managing cancer therapy-induced acneiform eruptions, with notable improvements in clinical severity and patient-reported outcomes. Additionally, a later onset of eruptions may be associated with a more favorable therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.